124 - Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial
Publication date: October 2018Source: Canadian Journal of Diabetes, Volume 42, Issue 5, SupplementAuthor(s): Subodh Verma, C. David Mazer, David Fitchett, Silvio Inzucchi, Jyothis T. George, Egon Pfarr, Hans J. Woerle, Bernard Zinman
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
More News: Canada Health | Cardiology | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Heart Failure | Jardiance | Peripheral Vascular Disease (PVD)